![ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization | CDC ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization | CDC](https://www.cdc.gov/vaccines/acip/recs/grade/images/novavax-04-adult-schedule.png?_=39257)
ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization | CDC
![Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall - Jun 15, 2023 Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall - Jun 15, 2023](https://ir.novavax.com/sites/default/files/images/novavax-ir-logo.jpg)
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall - Jun 15, 2023
![Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years — United States, July 13, 2022–March 13, 2023 | MMWR Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years — United States, July 13, 2022–March 13, 2023 | MMWR](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7231a4_NovavaxSafety_IMAGE_04Aug2023_1200x675.jpg?_=86488)